<DOC>
	<DOCNO>NCT02326064</DOCNO>
	<brief_summary>Ovarian cancer fifth lead cause cancer death woman worldwide . Most cancer manifest form ovarian cyst . Practitioners face two main difficulty . The first establish early diagnosis . The second differentiate benign tumor , malignant tumor . To date , one biological tumor marker routinely perform ovarian cyst , CA-125 ( cancer antigen 125 ) . Unfortunately , many study perform show sensitivity specificity unsatisfactory view severity disease . The principal investigator therefore propose evaluate new tumor marker , well use algorithm help differentiate benign malignant tumor , allow early diagnosis case ovarian cancer .</brief_summary>
	<brief_title>Prospective Multicenter Study Patients With Tumor Benign Ovarian Presumed Use Algorithms Such Roma RMI Tumor Markers Such CA125 HE4</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>patient undergo surgery ovarian cyst presume benign ovarian tumor ( accord rule IOTA ( International Ovarian Tumor Analysis Group ) group ) agreement participate study pregnant patient minor patient Patient guardianship , trusteeship , deprive liberty Patient ascites metastasis malignant ovarian mass presume rule IOTA group . Patient adnexal torsion suspect Patient unable understand propose study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>